Gsk Share Discussion Threads

[geckotheglorious] 26/7/2024 16:51

TraderMichael

There was never any evidence that the Covid vaccines prevented transmission but they were foisted on everyone who couldnt afford to say NO regardless.

Chance these jabs delay Dementia minimal.

All part of the sales gimmick to encourage uptake.

And NO I wont be taking my Flu vaccine annually either.

[dr biotech] 26/7/2024 14:38

Interesting that the study was not performed by GSK. Its hard to see the pathway on how it would work, but the data set is already substantial. I doubt it will ever be recommended as a prevention but it may increase the uptake of shingrix. There is a little more here

[tradermichael] 26/7/2024 10:12

But there's evidence:

Researchers compared some 100,000 people who had a new (GSK) shingles jab to a similar group who had an older one. On average, those who had the new jab had an extra 164 days free from a diagnosis of dementia over six years. Further work is needed to prove the link, scientists say.

[kernelthread] 25/7/2024 22:39

>>Stock price chart suggests the yanks are the ones trading on the short side here

Yes, that's quite likely, especially considering the problems are mostly caused by US ambulance chasers.

[geckotheglorious] 25/7/2024 19:00

Shingles could delay Dementia.
Yeah righto.

You're the last person I'd expect to fall for that speculative gusto

[dr biotech] 25/7/2024 18:13

Would be a big market...

[dope007] 24/7/2024 08:54

Second tranche added. Very unloved this stock isn't it

[dope007] 23/7/2024 15:34

Good data. Stock price chart suggests the yanks are the ones trading on the short side here

[tradermichael] 23/7/2024 15:33

GSK PLC on Tuesday reported "positive" data for testing on three different treatments by ViiV Healthcare, its majority-owned specialist HIV company.

The London-based pharmaceutical company firstly said ViiV Healthcare has shared 48-week findings from the phase 4 Paso Doble clinical trial investigating the two-drug regimen Dovato compared with the three-drug regimen Biktarvy for HIV.

Dovato comprises dolutegravir and lamivudine, while the Biktarvy regimen consists of bictegravir, emtricitabine and tenofovir alafenamide fumarate.

The trial, GSK said, focused on patients "who are virologically suppressed and who could benefit from treatment optimisation".

The 48-week results showed that virologically suppressed adults with HIV, if they switched to the Dovato regimen, demonstrated non-inferior efficacy in maintaining viral suppression compared with switching to Biktarvy.

Secondly GSK said ViiV, in which Pfizer Inc and Shionogi & Co Ltd also hold minority interests, announced positive data for HIV drug Apretude, or cabotegravir LA for PrEP, in pregnant people.

The new maternal safety and pregnancy outcomes and pharmacokinetic findings came from the HIV Prevention Trials Network's 084 open label extension, which evaluated cisgender women in sub-Saharan Africa who became pregnant while using Apretude for HIV pre-exposure prophylaxis, or PrEP.

"The findings showed that [Apretude] was generally well tolerated among pregnant women, and PK findings demonstrated that cabotegravir levels were maintained above those associated with HIV protection throughout the overall pregnancy period," GSK said.

Finally, GSK and ViiV announced phase 1 study results and in vitro data for VH4524184 or VH184, an investigational integrase strand transfer inhibitor or INSTI.

ViiV, GSK said, shared positive in vitro findings showing that VH184 retained its antiviral activity and could be effective in countering second-generation INSTI resistance.

Analysis of the phase 1 study, meanwhile, showed that PK and safety data supported the further development of VH184.

"The study showed VH184 achieved drug levels in the blood that could potentially exhibit sufficient antiviral activity against the clinically derived INSTI mutations seen in vitro," GSK explained.

[dplewis1] 22/7/2024 09:32

Morgan Stanley cuts target price to 1800p from 1860p

[tradermichael] 19/7/2024 13:22

GlaxoSmithKline (GSK) has announced the European Medicines Agency’s acceptance of their marketing application for Blenrep, a treatment for relapsed or refractory multiple myeloma. Promising results from two phase III trials, DREAMM-7 and DREAMM-8, indicated significant improvements in progression-free survival when compared to standard care. If approved, Blenrep could notably change the treatment landscape for this challenging blood cancer.

[tradermichael] 19/7/2024 09:56

IN @ 1520.928 ...... ;0)

[dope007] 19/7/2024 09:07

Bought a first Tranche at a smidge under 1508p

[dope007] 19/7/2024 08:46

Looking to make a first ever purchase here, but it looks like we are going to have a long summer on the UK stock market based on the last week or so. Dreadful performance despite massive undervaluation everywhere

[tradermichael] 16/7/2024 09:51

Drugs giant GSK is set to move its global headquarters back to central London, ending more than two decades at its Brentford base.

Around 3,000 employees will work from The Earnshaw building on the corner of New Oxford Street from Tuesday.

It marks the end of its time at the Brentford site in west London after the £315 million building was officially opened in 2002 by then prime minister Tony Blair.

GSK’s new HQ will house the firm’s leadership team – headed by chief executive Dame Emma Walmsley – as well as units supporting research and development, supply chain, commercial operations, corporate functions and its ViiV Healthcare specialist HIV joint venture.

It sees GSK return to central London, where the company traces its roots back to the Plough Court Pharmacy, founded in the City in 1715.

GSK said on announcing the new global HQ in December 2022 that the six-floor building would be designed with hybrid working in mind, including technology to support remote working, while also aiming to be energy efficient to help meet the firm’s 2030 net zero goals.

Dame Emma said at the time: “We are proud to call London our home and look forward to the opportunities for even closer collaboration with the city’s world-class science, academic and healthcare institutions.”

[tradermichael] 16/7/2024 09:39

Aug 23rd .... FDA decision on Jemperli Ph 3 RUBY trial

[alphorn] 12/7/2024 15:07

No! Very good. ;)

[bracke] 12/7/2024 13:49

Good day Alphorn

"GSK have anything for this huge market?"
==========================================

Was the pun intended?

[alphorn] 11/7/2024 15:31

Thx. Forgot about Alli. We don't hear much about that product; think that it has already gone generic?

[tradermichael] 11/7/2024 15:12

Take a look at GSK's alli® (orlistat 60 mg), launched 2009

[alphorn] 11/7/2024 14:48

For Pfizer holders - Pfizer is planning to test a daily weight-loss pill in mid-stage trials later this year on the experimental drug as its route into a market projected to be worth more than $130bn a year. The New York-based drugmaker said on Thursday that it would begin studies to evaluate the optimal dose of the weight-loss pill in the second half of this year. The pill is based on the compound danuglipron — a glucagon-like peptide, or GLP-1, similar to those used in popular weight-loss drugs produced by Novo Nordisk and Eli Lilly.

GSK have anything for this huge market?

[dplewis1] 11/7/2024 13:38

Guggenheim cuts target price to 1922p from 2092p

[chc15] 11/7/2024 13:35

Around 5% loss, bought in at 1600ish, can't see this moving anytime soon.

[tradermichael] 11/7/2024 13:08

What % did you lose?